GABAmimetic drugs in hyperkinetic involuntary movement disorders and their effects on mental status

C. A. Tamminga, G. K. Thaker

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

GABAmimetic drugs are effective in the treatment of hyperkinetic involuntary motor disorders like tardive dyskinesia. Several therapeutic pharmacologic strategies have been identified, including direct‐acting agonists, reuptake blockers, and degradation inhibitors. This pharmacologic response, in addition to providing clinical efficacy data, has led to the speculation that GABA is pathophysiologically involved in tardive dyskinesia. The most potent GABAmimetic compounds have psychotomimetic effects, but some of the weaker GABA agonists are clinically effective for dyskinesias without severe cognitive side effects. Thus, GABA agonists are likely to be available soon as practical treatments for tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)227-233
Number of pages7
JournalDrug Development Research
Volume21
Issue number3
DOIs
StatePublished - 1990

Keywords

  • affect
  • cognition
  • tardive dyskinesia

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'GABAmimetic drugs in hyperkinetic involuntary movement disorders and their effects on mental status'. Together they form a unique fingerprint.

Cite this